Cancer researchers testing radical change in drug trials

[Rich66]

http://www.fiercebiotech.com/story/c...ource=internal

UC San Francisco's Laura Esserman is taking a leading role in I-Spy 2, an innovative cancer trial that will rotate through up to 12 experimental cancer therapies in an effort to determine if a radical new approach can identify the right population for the right therapy on a much smaller budget.